These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36410355)

  • 1. De-Escalating Breast Cancer Therapy.
    Varsanik MA; Shubeck SP
    Surg Clin North Am; 2023 Feb; 103(1):83-92. PubMed ID: 36410355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalating de-escalation in breast cancer treatment.
    Sacchini V; Norton L
    Breast Cancer Res Treat; 2022 Sep; 195(2):85-90. PubMed ID: 35902432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perspectives on chemotherapy de-escalation in breast cancer.
    Rocque GB; Williams CP; Andrews C; Childers TC; Wiseman KD; Gallagher K; Tung N; Balch A; Lawhon VM; Ingram SA; Brown T; Kaufmann T; Smith ML; DeMichele A; Wolff AC; Wagner L
    Cancer Med; 2021 May; 10(10):3288-3298. PubMed ID: 33932097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Curigliano G; Burstein HJ; Winer EP; Gnant M; Dubsky P; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn HJ; Thürlimann B; ; André F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang CS; Huober J; Hussein K; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
    Ann Oncol; 2017 Aug; 28(8):1700-1712. PubMed ID: 28838210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-Escalating the Management of In Situ and Invasive Breast Cancer.
    Angarita FA; Brumer R; Castelo M; Esnaola NF; Edge SB; Takabe K
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.
    Esposito A; Viale G; Criscitiello C; Curigliano G
    Expert Rev Clin Pharmacol; 2019 Jan; 12(1):9-16. PubMed ID: 30466330
    [No Abstract]   [Full Text] [Related]  

  • 7. Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
    Andrews C; Childers TC; Wiseman KD; Lawhon V; Ingram S; Smith ML; Wolff AC; Wagner L; Rocque GB
    BMC Cancer; 2022 Feb; 22(1):141. PubMed ID: 35120494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards personalized treatment for early stage HER2-positive breast cancer.
    Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
    Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective therapeutic de-escalation in early stage breast cancer].
    Liapi A; Sarivalasis A; Jeanneret Sozzi W; Lelièvre L; Zaman K
    Rev Med Suisse; 2017 May; 13(563):1035-1038. PubMed ID: 28636294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies.
    Abuhadra N; Stecklein S; Sharma P; Moulder S
    Oncologist; 2022 Feb; 27(1):30-39. PubMed ID: 35305094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.
    McGee SF; Clemons M; Savard MF
    Curr Oncol; 2022 Jun; 29(6):4125-4137. PubMed ID: 35735438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.
    Zhu S; Li Y; Chen W; Fei X; Shen K; Chen X
    Front Oncol; 2021; 11():636266. PubMed ID: 33680973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalating and escalating systemic therapy of early breast cancer.
    Smith IE; Okines AFC
    Breast; 2017 Aug; 34 Suppl 1():S5-S9. PubMed ID: 28694014
    [No Abstract]   [Full Text] [Related]  

  • 14. De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.
    McCartney A; Vignoli A; Hart C; Tenori L; Luchinat C; Biganzoli L; Di Leo A
    Breast; 2017 Aug; 34 Suppl 1():S13-S18. PubMed ID: 28676389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial designs and results supporting treatment de-escalation and escalation.
    Regan MM; Barry WT
    Breast; 2017 Aug; 34 Suppl 1():S10-S12. PubMed ID: 28673539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
    Rosenberg AJ; Vokes EE
    Oncologist; 2021 Jan; 26(1):40-48. PubMed ID: 32864799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
    Barroso-Sousa R; Exman P; Tolaney SM
    Future Oncol; 2018 Apr; 14(10):937-945. PubMed ID: 29589471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
    Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
    Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.